Background: Myeloid differentiation factor 88 (MyD88) is an endogenous adaptor protein that coordinates the inflammatory response to agonists of the Toll-like receptor and interleukin-1 receptor families. This particular response is activated following myocardial ischemia and infarction and may represent a viable target for pharmacologic inhibition. The current study tested MyD88 inhibitors in a murine model of nonreperfused acute myocardial infarction (AMI).
INTRODUCTION
Acute myocardial infarction (AMI) is a primary cause of morbidity and mortality in the United States and worldwide. 1 Current treatments aim to prompt reperfusion of ischemic tissue and reduction of myocardial oxygen requirements. Despite treatment advances, complete reperfusion is not always achievable and restoration of arterial patency does not ensure reperfusion of myocardial tissue, and patient with poor reperfusion are at higher risk for pathologic cardiac enlargement, heart failure, and death. 2, 3 During the acute phase of infarction, damage to myocardial tissue promotes the release of proinflammatory mediators within the myocardium. 4 This inflammatory response is associated with increased myocardial cell death (apoptosis) and pathologic remodeling of the heart during the postinfarction period. 4, 5 The complexity and redundancy of the inflammatory response may represent a limitation to the success of targeted anticytokine therapy in AMI and heart failure. 6 Independent lines of research have described a role of interleukin (IL)-1, 7, 8 IL-18, 9,10 IL-33, 11, 12 and Toll-like receptor agonists [13] [14] [15] in AMI and heart failure. These cytokines/mediators all share the same family of receptor/accessory proteins that share a sequence homology known as the Toll/IL-1 receptor (TIR) domain. 16, 17 The myeloid differentiation factor 88 (MyD88) is an innate adaptor protein that binds to the TIR domain to coordinate the cellular response to the different agonists. 16, 17 Upon binding with one of the TIR receptor complexes, MyD88 homodimers activate the IL-1 associated kinase (IRAK) complex which phosphorylates downstream kinases and transcription factors [ie, nuclear factor kB (NF-kB)].
Several reports have linked MyD88 and the innate immune response to myocardial response following ischemia. Mice with genetic deletion of MyD88 18, 19 or IRAK-4 20 expression have smaller infarcts in AMI models induced by transient ischemia followed by reperfusion or permanent coronary ligation, respectively. From a translational standpoint, it is important to consider that effective reperfusion is not obtained in all patients presenting with AMI; many patients present late for reperfusion or have evidence of poor myocardial reperfusion. These are the patients who incur the highest risk of developing pathologic cardiac enlargement and heart failure and for whom there is an urgent need for adjunctive therapy. 2 The potential of MyD88 inhibition to prevent heart failure following AMI has not been investigated. We hypothesized that pharmacologic inhibition of MyD88 would provide advantageous TIR blockade and prevent pathologic cardiac enlargement in a model of AMI without reperfusion, representing the basis for a novel treatment target for the prevention of heart failure following AMI. We hereby report the effects of 2 novel pharmacologic MyD88 inhibitors 22, 23 that ameliorated cardiac enlargement following AMI. 
MATERIALS AND METHODS

Animals
Drugs
ST2825 is a small molecule that mimics the TIR domain of the MyD88 protein and inhibits homodimerization, provided at no cost by Sigma Tau (Pomezia, Italy). IMG2005 is a synthetic oligopeptide with a structure similar to ST2825 that also inhibits homodimerization, purchased from Imgenex Corporation (San Diego, CA). As IMG2005 had not been previously evaluated for in vivo use, the initial dose (1 mg/kg) was extrapolated from oligopeptides of similar size that share a common antennapedia sequence with IMG2005. 21, 22 All drugs were given intraperitoneally.
Small Interfering RNA
A previously validated protocol was used to explore decreasing doses of small interfering RNA (siRNA; 1.5, 1.0, 0.45, 0.15, 0.1 mg/g). 24 The siRNA was purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA), reconstituted in RNAase-free water, mixed with an equal volume of siPORT amine (Applied Biosystems, Austin, TX, room temperature, 30 minutes) to promote cell internalization, and then injected into the mice. A scrambled nontargeted siRNA sequence was used as a control. Western blots using primary antibodies raised against MyD88 (produced in rabbit, 1:500 dilution, Sigma-Aldrich Corp., St. Louis, MO) and b-actin (produced in mouse clone AC-40, purified immunoglobulin, dilution 1:5000, Sigma Aldrich Corp.) were performed to determine silencing efficacy. Proteins were extracted from the heart tissue homogenate (Ripa buffer and proteases cocktail inhibitor, Sigma Aldrich Corp.), transferred to polyvinylidene fluoride membranes (0.45 mm pore size), and incubated with 3% milk for 2 hours at room temperature. Chemiluminescence detection was performed with Immobilon Western Chemiluminescent horse radish peroxidase substrate (ECL, Millipore, Billerica, MA) and quantified using Scion Image software (Scion Corp., Frederick, MD).
Interleukin-6 Plasma Levels
Interleukin-6 levels were used as a surrogate of NF-kB activity following IL-1b (3 mg/kg) challenge. 25 Blood was drawn by direct cardiac puncture at sacrifice 4 hours after IL-1b challenge, transferred to heparin tubes and centrifuged at 2000g for 15 minutes. The supernatant was collected and stored at 220°C until subsequent analysis. A quantitative sandwich enzyme immunoassay (Quantikine, RnD Systems, Minneapolis, MN) was used according to the manufacturer's instructions.
Myocardial Infarction Protocol
The animals were anesthetized with injection of pentobarbital (70 mg/kg IP), intubated orotracheally, and ventilated on a positive-pressure ventilator. The tidal volume was set at 0.2 mL, and the respiratory rate was adjusted to 133 cycles/min. All surgical procedures were carried out under sterile conditions, as described previously. 7 A left thoracotomy was performed at the fourth intercostal space, and the heart was exposed by stripping the pericardium. The left descending coronary artery was then identified and ligated with a 7.0 silk ligature.
Experimental Groups
Mice underwent surgical coronary artery ligation to simulate and random assignment to 1 of 5 treatment groups ( underwent echocardiography at baseline and 7 days after infarction. Upon completion of echocardiography, mice were sacrificed (70 mg/kg pentobarbital injection) and the hearts immediately removed and fixed in 10% formalin (at least 48 hours) for subsequent histologic evaluation.
Doppler Echocardiography
Doppler echocardiography was performed using the Vevo770 imaging system (VisualSonics Inc, Toronto, Canada) to obtain measurements at baseline and 7 days later, immediately before sacrificing the animal. Light anesthesia was used during the measurement with injection of pentobarbital (30 mg/kg IP). A liquid depilatory was used to remove the fur and the mice were placed on a heated platform. Ultrasound gel was used on the thorax to optimize visibility during the exam. A 30-MHz probe was utilized to obtain 2-dimensional and M-mode images from the parasternal short-axis view at the level of the papillary muscles, according to the recommendations of the American Society of Echocardiography. 26 M-mode images of the LV were obtained to measure systolic and diastolic wall thickness (anterior and posterior) and LV end-systolic and end-diastolic diameters (LVESD and LVEDD, respectively). LV fractional shortening was calculated as (LVEDD 2 LVESD)/LVEDD 3 100. LV ejection fraction was calculated with the Teichholz formula. LV mass was calculated based on LVEDD, posterior wall diastolic thickness (PWDT), and anterior wall diastolic thickness (AWDT) using the Deveraux formula as 0.8 3 [1.04(LVEDD + PWDT + AWDT) 3 2 (LVEDD) 3 ] + 0.6 g. 26 The investigators performing and reading the echocardiogram were blinded to treatment allocation.
Infarct Scar
Myocardial fibrosis was measured 7 days after infarction to assess infarct scar dimensions in the LV. Heart sections were stained with Masson trichrome (Sigma-Aldrich). The areas of fibrosis and the whole left ventricle were determined by computer morphometry using a Bioquant imaging software. The ratio was used to compute scar area expressed as a percentage of the left ventricle.
Statistics
All measurements are expressed as group means 6 SE. Discrete variables were presented as absolute and percent value. Differences between the groups were analyzed using the 1-way ANOVA and changes in echocardiography and infarct size were analyzed using the random effects ANOVA for repeated-measures to determine the main effect of time, group, and time-by-group interaction, using Dunnett test for comparison between the different groups. Statistical differences were considered significant if the P value was , 0.05. All authors had full access to the data and take responsibility for its integrity.
RESULTS
Protein Expression
Western blot analysis showed effective suppression of MyD88 expression in mice treated with MyD88-targeted siRNA (at 24 hours after siRNA administration) compared with those treated with nontargeted scrambled siRNA (Fig. 2) . MyD88 expression remained suppressed for up to 72 hours and returned to baseline at approximately 96 hours after single-dose siRNA administration (data not shown).
Interleukin-6 Levels as Surrogate for NF-kB Activity IL-1b (3 mg/kg) led to a significant increase in plasma IL-6 levels at 4 hours (Fig. 3) . Mice pretreated with MyD88-targeted siRNA (24 hours earlier) had significantly lower IL-6 levels after IL-1b challenge than controls receiving IL-1b alone and mice pretreated with scrambled nontargeted siRNA followed by IL-1b (P , 0.05 for both comparison). Similarly, mice pretreated with ST2825 (25 mg/kg) or IMG2005 (1 mg/kg) had significantly lower IL-6 levels following IL-1b challenge compared with mice receiving IL-1b without pretreatment (Fig. 3) .
Cardiac Enlargement Following AMI
Changes in cardiac dimensions after AMI are surrogate endpoints for heart failure-related morbidity and mortality. In terms of hypertrophy, saline-treated mice experienced a significant change in LV mass as assessed by echocardiography at 7 days after coronary ligation surgery [90 6 3 mg (baseline) versus 110 6 4 mg (7 days 
Infarct Size
Treatment with MyD88-targeted siRNA, ST2825, or IMG2005 did not affect LV infarct scar formation (as measured by trichrome fibrosis staining at 7 days) when compared with saline control-treated mice or mice treated with scrambled nontargeted siRNA (all P values . 0.05, Fig. 5 ).
DISCUSSION
Myocardial ischemia and ensuing cell death during AMI initiates a complex inflammatory response characterized by multiple mediators and pathologic cardiac enlargement. 4, 5 The results of the current study identify MyD88, an adaptor protein tightly linked to innate immunity, as a potential target for treatment. Indeed, MyD88 inhibition using pharmacologic inhibitors and silencing RNA led to significantly less cardiac enlargement in a model of AMI due to permanent left coronary ligation in the mouse. From a pathophysiologic standpoint, the similarity of the effects obtained by blocking MyD88 directly and by blocking the individual TIR agonists IL-1, IL-18, and FIGURE 3. IL-6 concentration as a surrogate for NF-kB activity. Mice received injection with IL-1b (3 mg/kg IP) to stimulate IL-6 production followed by blood sampling at 4 hours (N $ 4 per group). IL-6 concentration was determined by quantitative ELISA. Pretreatment with MyD88-targeted siRNA or pharmacologic MyD88 inhibitors blunted IL-1 effects on IL-6 concentration. toll-like receptor suggests that MyD88 modulates cardiac remodeling at a signal convergence point downstream of such agonists. 16, 17 From a clinical standpoint, there is an urgent need to identify viable therapeutic targets to modulate inflammation after AMI. [2] [3] [4] 29 As ventricular dilation is an established predictor of progression to heart failure, the prevention of cardiac enlargement by pharmacologic inhibition of MyD88 may represent a completely novel approach to prevent heart failure. 32 Such a hypothesis would clearly require validation in human clinical trials.
The finding of a significant role for MyD88 signaling in our model of nonreperfused AMI is in keeping with prior observation of models of AMI of lesser severity (ie, transient ischemia). 18, 19 Nevertheless, some differences in the findings are obvious and need to be addressed. First, MyD88 inhibition by either pharmacologic inhibition or silencing RNA did not show an infarct sparing effect, whereas previous findings describe a smaller infarct in MyD88-deficient mice. 18, 19 There are several differences in the experimental setting that may explain this discrepancy: first, the earlier studies used genetically engineered mice that may develop compensatory alterations in parallel signaling pathways to counteract permanent abrogation of MyD88 signaling. In this case, transient interruption of MyD88 (using pharmacologic inhibitors and siRNA) may constitute a more translatable model of MyD88 blockade than knockout models with permanent MyD88 deletion. Second, different models of AMI have been used (transient ischemia versus prolonged ischemia) that vary in their pathophysiologic evolution and inflammatory response. 30 The effects of transient ischemia/reperfusion in healthy mice may be substantially different from those of plaque rupture, thrombosis, and reperfusion in chronically atherosclerotic human patients. Third, pharmacologic inhibitors and silencing RNA are not perfectly specific and may have influenced pathways beyond MyD88 that our assays were not designed to detect. The extent and magnitude of these unanticipated effects are, by definition, unknown and difficult to quantify.
The effects of MyD88 inhibition in our model of nonreperfused AMI model due to coronary ligation is consistent with the findings of more favorable cardiac remodeling, independent of infarct size in mice with genetic deletion of the IRAK-4 gene subjected to permanent ligation. 21 In the current study, MyD88 interruption did not elicit any change in infarct size. This finding may be partially attributed to the model of permanent coronary ligation, which may limit the potential for infarct sparing. Nonetheless, the finding of reduced LV enlargement independent of infarctsparing effects may prove to be of significant translational value. Due to the proficiency of contemporary reperfusion techniques, infarct size is primarily determined by the success of coronary reperfusion. Moreover, patients with poor reperfusion are at highest risk of heart failure and may obtain the most benefit from MyD88 inhibition. 30 The exact mechanism by which MyD88 inhibition prevents cardiac enlargement following AMI is also not established. Our observations confirm MyD88 as an important signaling node but do not clarify the downstream effects. Further studies are needed to explore the effects of MyD88 at the cellular and molecular levels. For example, MyD88-independent signaling of TIR receptors has been described in pathologies other than cardiac. 16, 17 Whether these MyD88-independent pathways are involved or not in cardiac remodeling is unclear.
The current finding that MyD88 inhibition may prevent cardiac enlargement and hypertrophy independent of any benefit on LV function highlights the potential dissociation between cardiac function and survival. This may correlate with previous human clinical trials, such as the Vasodilator Heart Failure Trial study, in which enalapril led to a lesser improvement in ejection fraction but to a greater survival than hydralazine/isosorbide. 27, 31 The divergence of effect on cardiac remodeling and on function in our study may however be due, in part, to the short duration of follow-up (1 week) after infarction. Indeed, the initial increase of LV volumes after AMI serves the purpose of preserving the stroke volume; whereas the late LV dilation becomes a mechanism of reduced ejection fraction and progression to heart failure. 27, 31, 32 Our findings also suggest that some degree of hypertrophy is essential to maintain LV function after AMI and the lack of compensatory hypertrophy following MyD88 blockade may have contributed to the resultant neutral effect on LV function. Although clinical measurements of LV function do predict outcomes after AMI, clinical studies of angiotensin-converting enzyme inhibitors in post-AMI patients found that LV dilation was a more powerful predictor of mortality than LV function. 31, 32 In summary, we found that pharmacologic inhibition of MyD88 in vivo attenuates pathologic LV dilation and hypertrophy in a mouse model of nonreperfused AMI independent of infarct size. MyD88 is an important adaptor protein at the convergence of multiple proinflammatory pathways in innate immunity. Our findings suggest that MyD88 inhibition may become a novel pharmacologic target for future translational investigation for the prevention of heart failure following AMI.
